Blue Capital Inc. bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,922 shares of the exchange traded fund’s stock, valued at approximately $478,000.
A number of other large investors also recently added to or reduced their stakes in the company. Compound Planning Inc. acquired a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter valued at $1,319,000. Connective Capital Management LLC acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth about $977,000. Axxcess Wealth Management LLC purchased a new position in SPDR S&P Biotech ETF during the 4th quarter valued at about $431,000. Corient Private Wealth LLC boosted its holdings in SPDR S&P Biotech ETF by 40.8% during the 4th quarter. Corient Private Wealth LLC now owns 54,511 shares of the exchange traded fund’s stock valued at $6,646,000 after acquiring an additional 15,808 shares during the period. Finally, Galaxy Group Investments LLC acquired a new position in SPDR S&P Biotech ETF in the 4th quarter valued at about $1,036,000.
SPDR S&P Biotech ETF Price Performance
Shares of NYSEARCA:XBI opened at $140.72 on Friday. The firm has a market capitalization of $8.98 billion, a PE ratio of 11.47 and a beta of 0.85. The firm’s 50-day moving average is $133.36 and its two-hundred day moving average is $127.61. SPDR S&P Biotech ETF has a 1 year low of $80.90 and a 1 year high of $143.46.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
